Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Eating Habits and Behavior in People Affected by Lipodystrophy: Observational Study (lipo-diet_2024)

11 novembre 2026 mis à jour par: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Title: Dietary Habits and Eating Behavior in People with Lipodystrophy: An Observational Study.

Purpose: The purpose of this study is to investigate and analyze the dietary habits and eating behaviors of patients diagnosed with lipodystrophy. Since there is currently a lack of specific data on how these patients approach nutrition, this research aims to provide essential information to improve nutritional guidelines. Additionally, the study seeks to understand if there is a relationship between eating behaviors and the patients' clinical data, such as blood test results and body measurements (anthropometric parameters).

Study Design:

This is an observational, cross-sectional, single-center study with a 2-year enrollment period. Participants will be recruited during their regular medical visits at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.

During the study, the following activities will take place:

Clinical Data Collection: Researchers will record body measurements and blood test results as part of standard clinical practice.

Questionnaires: Patients will be asked to complete four specific questionnaires (available in Italian and English) regarding their food frequency, eating behavior patterns, tendencies toward orthorexia, and physical activity levels.

Format: These questionnaires can be completed electronically via a RedCap link (taking approximately 20-30 minutes) or on paper.

Eligibility:

Inclusion Criteria: Adults (18 years or older) with a confirmed diagnosis of lipodystrophy who provide informed consent.

Exclusion Criteria: Patients with HIV-related lipodystrophy or those who cannot understand the languages in which the questionnaires are provided.

Duration and Participation:

The study will last a total of 2 years and 6 months. The first 2 years are dedicated to patient selection and recruitment, followed by 6 months for data analysis. The researchers aim to enroll 30 participants.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

1. Background and RationaleLipodystrophy refers to a rare and heterogeneous group of syndromes characterized by the total or partial loss of subcutaneous adipose tissue. This condition leads to severe metabolic complications, such as marked insulin resistance, early-onset diabetes, severe hypertriglyceridemia, and hepatic steatosis (fatty liver).A key factor in this pathology is hypoleptinemia (deficiency of the hormone leptin), which plays a crucial role in regulating energy balance. The lack of leptin disrupts satiety signals, often resulting in hyperphagia (insatiable hunger), with energy intake potentially exceeding requirements by up to 40%. While lifestyle and dietary modifications are considered the "cornerstone" of treatment, there is currently a significant lack of structured data and evidence-based nutritional guidelines for these patients.2. Study ObjectivesPrimary Objective: To identify, analyze, and describe the lifestyle of patients with a focus on dietary habits, eating behaviors, and physical activity.Secondary Objective: To explore the relationship between these behaviors and clinical data, including anthropometric measurements and biochemical (blood) parameters.3. Study Population and EligibilityThe study aims to enroll 30 patients managed at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.Inclusion Criteria: Male and female adults (≥ 18 years old) with a confirmed diagnosis of lipodystrophy who provide written informed consent.Exclusion Criteria: Patients with HIV-related lipodystrophy or those unable to understand the languages in which the questionnaires are provided.4. Study Design and MethodologyThis is a prospective, cross-sectional, observational, single-center study. Data will be collected during routine endocrinological visits through the following means:A. Clinical and Biochemical ParametersAnthropometric Data: Weight, height, BMI, waist and hip circumference, and body fat percentage.Biochemical Data: Fasting plasma glucose, HbA1c, full lipid profile (total cholesterol, HDL, LDL, triglycerides), liver enzymes (AST, ALT), kidney function, insulin levels, and HOMA-IR.B. Self-Assessment QuestionnairesParticipants will complete four validated tools (estimated time: 30 minutes, via RedCap or paper):Food Frequency Questionnaire (FFQ): To assess the intake frequency of 36 food items over the past 12 months.Three-Factor Eating Questionnaire (TFEQ-R18): To evaluate cognitive restraint, uncontrolled eating, and emotional eating.Teruel Orthorexia Scale (TOS): To measure orthorexic tendencies (obsession with healthy eating) in both "healthy" and "nervosa" dimensions.IPAQ-Short Form: To categorize physical activity levels as low, moderate, or high.5. Study Duration and AnalysisThe total study duration is 2 years and 6 months. This includes 2 years for patient recruitment and 6 months for data analysis. Statistical analysis will be performed using STATA 19 SE, comparing the observed dietary data with the 2024 LARN guidelines (Nutrient and Energy Reference Intake Levels) to identify deviations and correlations with metabolic health.

Type d'étude

Observationnel

Inscription (Estimé)

30

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Bologna
      • Bologna, Bologna, Italie, 40138
        • Recrutement
        • IRCSS Azienda Ospedaliero-Universitaria di Bologna

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

N/A

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Male and female patients over the age of 18 attending the outpatient service of the Endocrinology and Diabetes Prevention and Treatment Unit - U. Pagotto - IRCCS AOU in Bologna, Policlinico Sant'Orsola - Malpighi during their visit to the dedicated clinic.

La description

Inclusion Criteria:

  • Obtaining informed consent
  • Age 18 or older at the time of diagnosis
  • Diagnosis of lipodystrophy

Exclusion Criteria:

  • Failure to understand the language in which the questionnaires are administered
  • HIV-related lipodystrophy

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Food Frequency Questionnaire (FFQ)
Délai: baseline
baseline
Three-Factor Eating Questionnaire R-18 (TFEQ-R18)
Délai: baseline

Assessment of eating behavior using the 18-item validated questionnaire, evaluating three subscales: Cognitive Restraint (CR), Uncontrolled Eating (UE), and Emotional Eating (EE). Items are scored on a 4-point scale and converted to a 0-100 scale per domain, where higher scores indicate higher expression of the specific behavior.

baseline
Teruel Orthorexia Scale (TOS)
Délai: baseline
baseline
International Physical Activity Questionnaire - Short Form (IPAQ-Short Form)
Délai: baseline
baseline

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Body Mass Index (BMI)
Délai: baseline

Assessment of body weight status using BMI, calculated as weight in kilograms divided by height in meters squared (kg/m2).

baseline
Body Fat Percentage
Délai: baseline

Evaluation of total body fat composition measured via anthropometric assessment/bioelectrical impedance analysis (BIA).

baseline
Waist-to-Hip Ratio (WHR)
Délai: baseline

Assessment of abdominal obesity calculated as waist circumference divided by hip circumference.

baseline
Fasting Blood Glucose
Délai: baseline

Laboratory evaluation of serum/plasma fasting glucose concentration (mg/dL).

baseline
Glycated Hemoglobin (HbA1c)
Délai: baseline

Laboratory evaluation of glycated hemoglobin level (mmol/mol).

baseline
Fasting Serum Insulin
Délai: baseline

Laboratory evaluation of basal insulin levels micromol/mL.

baseline
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Délai: baseline

index score

baseline
Lipid Profile Parameters
Délai: baseline
baseline

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 septembre 2025

Achèvement primaire (Estimé)

30 septembre 2027

Achèvement de l'étude (Estimé)

31 mars 2028

Dates d'inscription aux études

Première soumission

4 mars 2026

Première soumission répondant aux critères de contrôle qualité

11 novembre 2026

Première publication (Réel)

16 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 mars 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner